Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results9

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results9

Views

Views
November 20234
December 20231
January 20241
February 20240
March 20241
April 20240
May 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Spain2
 

Top cities views

Views
Boardman2
Berga2
Chicago1